{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=75&status=ACTIVE_NOT_RECRUITING",
    "query": {
      "status": "ACTIVE_NOT_RECRUITING",
      "page": 75
    },
    "page_size": 10
  },
  "pagination": {
    "page": 75,
    "page_size": 10,
    "total_count": 10535,
    "total_pages": 1054,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=76&status=ACTIVE_NOT_RECRUITING&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=74&status=ACTIVE_NOT_RECRUITING&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T08:17:20.976Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05565586",
      "title": "Impact of High Dietary Fiber on Microbiome and Vaccine Responses",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "High-Fiber Diet (HFD)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Prebiotic Food-Enriched Diet (PreFED)",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2022-08-23",
      "completion_date": "2029-01-02",
      "has_results": false,
      "last_update_posted_date": "2026-08-14",
      "last_synced_at": "2026-11-15T08:17:20.976Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05565586"
    },
    {
      "nct_id": "NCT04285086",
      "title": "Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Essential Thrombocythemia"
      ],
      "interventions": [
        {
          "name": "Ropeginterferon alfa-2b",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Anagrelide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "PharmaEssentia",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 174,
      "start_date": "2020-08-25",
      "completion_date": "2029-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-11-15T08:17:20.976Z",
      "location_count": 4,
      "location_summary": "Scottsdale, Arizona • St Louis, Missouri • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04285086"
    },
    {
      "nct_id": "NCT03911973",
      "title": "Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "TNBC - Triple-Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Gedatolisib",
          "type": "DRUG"
        },
        {
          "name": "Talazoparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kari Wisinski",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2019-04-17",
      "completion_date": "2024-07",
      "has_results": false,
      "last_update_posted_date": "2024-06-07",
      "last_synced_at": "2026-11-15T08:17:20.976Z",
      "location_count": 5,
      "location_summary": "Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 1 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03911973"
    },
    {
      "nct_id": "NCT04495153",
      "title": "CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Aglatimagene besadenovec",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Valacyclovir",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care anti-PD-1/PD-L1 (ICI)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Candel Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2020-10-13",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-11-05",
      "last_synced_at": "2026-11-15T08:17:20.976Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • Farmington, Connecticut • New Haven, Connecticut + 10 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04495153"
    },
    {
      "nct_id": "NCT00882895",
      "title": "Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin"
      ],
      "interventions": [
        {
          "name": "Stem cell infusion",
          "type": "PROCEDURE"
        },
        {
          "name": "TLI",
          "type": "PROCEDURE"
        },
        {
          "name": "Anti-thymocyte globulin",
          "type": "DRUG"
        },
        {
          "name": "Solumedrol",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 18,
      "start_date": "2009-05-05",
      "completion_date": "2028-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-02",
      "last_synced_at": "2026-11-15T08:17:20.976Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00882895"
    },
    {
      "nct_id": "NCT03594981",
      "title": "Adoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation/Infection or Prophylaxis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Viral Infection"
      ],
      "interventions": [
        {
          "name": "CMV/AdV /EBV/BKV specific T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Catherine Bollard",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 2,
      "start_date": "2018-01-24",
      "completion_date": "2026-12-15",
      "has_results": false,
      "last_update_posted_date": "2026-08-14",
      "last_synced_at": "2026-11-15T08:17:20.976Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • Houston, Texas",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03594981"
    },
    {
      "nct_id": "NCT05628207",
      "title": "Evaluation of the SCALED (SCaling AcceptabLE cDs)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Traumatic Brain Injury",
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Observational",
          "type": "OTHER"
        },
        {
          "name": "Observational-control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15000,
      "start_date": "2023-05-16",
      "completion_date": "2027-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-11-15T08:17:20.976Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05628207"
    },
    {
      "nct_id": "NCT05273307",
      "title": "Addressing Taste Dysfunction With Miraculin in Head and Neck Cancer Patients Receiving Radiation Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "Taste Dysfunction"
      ],
      "interventions": [
        {
          "name": "Miraculin",
          "type": "DRUG"
        },
        {
          "name": "Miracle Fruit Placebo Cube",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2022-03-04",
      "completion_date": "2026-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-11-15T08:17:20.976Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05273307"
    },
    {
      "nct_id": "NCT01688492",
      "title": "Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 54,
      "start_date": "2012-09",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-11-15T08:17:20.976Z",
      "location_count": 3,
      "location_summary": "Evanston, Illinois • New York, New York • Portland, Oregon",
      "locations": [
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01688492"
    },
    {
      "nct_id": "NCT06332092",
      "title": "FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "FID007",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fulgent Pharma LLC.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2024-04-10",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-11-15T08:17:20.976Z",
      "location_count": 6,
      "location_summary": "Fayetteville, Arkansas • Los Angeles, California • Tampa, Florida + 3 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06332092"
    }
  ]
}